1. Evaluation of cost and infusion-related reactions among intravenous trastuzumab, subcutaneous trastuzumab, and trastuzumab biosimilars at an academic medical center
   Daijah M Davis et al, 2024, Journal of Oncology Pharmacy Practice CrossRef